Current Hematologic Malignancy Reports最新文献_第4页

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. 晚期慢性髓性白血病管理的最新进展。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-08-31 DOI: 10.1007/s11899-023-00709-4

Nicholas J Short, Jayastu Senapati, Elias Jabbour

引用次数: 0

Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions. 测量端粒长度的实验和计算方法：最新进展和未来方向。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-11-10 DOI: 10.1007/s11899-023-00717-4

Alejandro Ferrer, Zachary D Stephens, Jean-Pierre A Kocher

{"title":"Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions.","authors":"Alejandro Ferrer, Zachary D Stephens, Jean-Pierre A Kocher","doi":"10.1007/s11899-023-00717-4","DOIUrl":"10.1007/s11899-023-00717-4","url":null,"abstract":"Purpose of review: The length of telomeres, protective structures at the chromosome ends, is a well-established biomarker for pathological conditions including multisystemic syndromes called telomere biology disorders. Approaches to measure telomere length (TL) differ on whether they estimate average, distribution, or chromosome-specific TL, and each presents their own advantages and limitations.Recent findings: The development of long-read sequencing and publication of the telomere-to-telomere human genome reference has allowed for scalable and high-resolution TL estimation in pre-existing sequencing datasets but is still impractical as a dedicated TL test. As sequencing costs continue to fall and strategies for selectively enriching telomere regions prior to sequencing improve, these approaches may become a promising alternative to classic methods. Measurement methods rely on probe hybridization, qPCR or more recently, computational methods using sequencing data. Refinements of existing techniques and new approaches have been recently developed but a test that is accurate, simple, and scalable is still lacking.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10709248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72013872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders. 端粒生物学障碍患者的遗传咨询和家庭筛查建议。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-10-03 DOI: 10.1007/s11899-023-00713-8

Laura Ongie, Hannah A Raj, Katie Barrett Stevens

引用次数: 0

Central Nervous System Relapse in T and NK cell Lymphomas. T 细胞和 NK 细胞淋巴瘤的中枢神经系统复发。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1007/s11899-023-00710-x

Eleanor P Taranto, Stefan K Barta, Rahul S Bhansali

{"title":"Central Nervous System Relapse in T and NK cell Lymphomas.","authors":"Eleanor P Taranto, Stefan K Barta, Rahul S Bhansali","doi":"10.1007/s11899-023-00710-x","DOIUrl":"10.1007/s11899-023-00710-x","url":null,"abstract":"Purpose of review: T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high rates of mortality. Central nervous system relapse carries significant morbidity, though management is largely extrapolated from literature in B cell neoplasms. As such, outcomes for central nervous system involvement in T/NK cell lymphomas are dismal with no standard of care. In this review, we discuss the epidemiology of central nervous system relapse in T/NK cell lymphomas and critically analyze available literature regarding prophylaxis and treatment.Recent findings: Retrospective studies of central nervous system involvement in T/NK cell lymphomas have been limited by small sample sizes and heterogeneity of subtypes, though sites of extranodal involvement and disease subtypes are consistently reported as risk factors. Compelling evidence for the use of central nervous system-directed prophylactic therapy has not yet been established, though recent reports of central nervous system activity with novel agents may suggest promising therapeutic options. The overall rarity of T and NK cell lymphomas has precluded adequate study of prophylaxis and treatment of central nervous system relapse. Collaborative efforts are needed to better define strategies to address CNS disease in T/NK cell lymphomas. These should involve the use of targeted agents, which may hold an advantage over traditional cytotoxic drugs.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10058085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measurable Residual Disease Monitoring in Lymphoma. 淋巴瘤可测量残留疾病监测。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-11-06 DOI: 10.1007/s11899-023-00715-6

Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng

{"title":"Measurable Residual Disease Monitoring in Lymphoma.","authors":"Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng","doi":"10.1007/s11899-023-00715-6","DOIUrl":"10.1007/s11899-023-00715-6","url":null,"abstract":"Purpose of review: The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as an adjunctive tool in caring for hematologic cancer patients is expanding. This holds true for lymphoma where these biomarkers are being explored as a means of genotyping and quantifying disease. Regarding the latter, they can be used to monitor measurable residual disease (MRD) during and after treatment. This holds potential for aiding clinical decisions amidst treatment, detecting earlier relapse, and improving prognostication. Here, we review the evidence to support these applications in a variety of lymphoma subtypes.Recent findings: Numerous clinical trials across a variety of lymphomas have demonstrated value in MRD monitoring. MRD monitoring is often prognostic for progression free survival (PFS) and even overall survival (OS) at several time points in a disease course, particularly when utilizing serial measurements. With regards to tailoring treatment, there are a growing number of trials examining MRD-adaptive treatment strategies to intensify or de-escalate treatment to individualize care. Lastly, MRD monitoring has been utilized successfully in detecting earlier relapse when compared to more standard methods of clinical surveillance such as radiographic assessment. Although not routinely implemented into clinical practice, MRD monitoring in lymphoma is helping shape the future landscape of this disease by aiding in prognostication, guiding therapy, and detecting earlier relapse. Steps to standardize and further examine this technology prospectively are being taken to bring MRD monitoring to the forefront of the field.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. 开发针对 T 细胞急性淋巴细胞白血病/淋巴瘤的靶向疗法。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-07-25 DOI: 10.1007/s11899-023-00706-7

Adam S DuVall, Austin Wesevich, Richard A Larson

引用次数: 0

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases. JAK抑制剂治疗骨髓增生性疾病之旅。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-07-03 DOI: 10.1007/s11899-023-00702-x

Andrea Duminuco, Elena Torre, Giuseppe A Palumbo, Claire Harrison

{"title":"A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.","authors":"Andrea Duminuco, Elena Torre, Giuseppe A Palumbo, Claire Harrison","doi":"10.1007/s11899-023-00702-x","DOIUrl":"10.1007/s11899-023-00702-x","url":null,"abstract":"Purpose of review: Chronic myeloproliferative neoplasms (MPN) represent a group of diseases characterised by constitutive activation of the JAK/STAT pathway in a clonal myeloid precursor. The therapeutic approach aims to treat the symptom burden (headache, itching, debilitation), splenomegaly, slow down the fibrotic proliferation in the bone marrow and reduce the risk of thrombosis/bleeding whilst avoiding leukaemic transformation.Recent findings: In recent years, the advent of JAK inhibitors (JAKi) has significantly broadened treatment options for these patients. In myelofibrosis, symptom control and splenomegaly reduction can improve quality of life with improved overall survival, not impacting progression into acute leukaemia. Several JAKi are available and used worldwide, and combination approaches are now being explored. In this chapter, we review the approved JAKi, highlighting its strengths, exploring potential guidelines in choosing which one to use and reasoning towards future perspectives, where the combinations of therapies seem to promise the best results.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress? 慢性淋巴细胞白血病的Richter转化我们正在取得进展吗？

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-06-09 DOI: 10.1007/s11899-023-00701-y

Hadiyah Y Audil, Samuel R Kosydar, Daniel P Larson, Sameer A Parikh

{"title":"Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?","authors":"Hadiyah Y Audil, Samuel R Kosydar, Daniel P Larson, Sameer A Parikh","doi":"10.1007/s11899-023-00701-y","DOIUrl":"10.1007/s11899-023-00701-y","url":null,"abstract":"Purpose of review: The treatment paradigm of chronic lymphocytic leukemia (CLL) has dramatically changed with the advent of novel targeted agents over the past decade. Richter transformation (RT), or the development of an aggressive lymphoma from a background of CLL, is a well-recognized complication of CLL and carries significantly poor clinical outcomes. Here, we provide an update on current diagnostics, prognostication, and contemporary treatment of RT.Recent findings: Several genetic, biologic, and laboratory markers have been proposed as candidate risk factors for the development of RT. Although a diagnosis of RT is typically suspected based on clinical and laboratory findings, tissue biopsy is essential for histopathologic confirmation of diagnosis. The standard of care for RT treatment at this time remains chemoimmunotherapy with the goal of proceeding to allogeneic stem cell transplantation in eligible patients. Several newer treatment modalities are being studied for use in the management of RT, including small molecules, immunotherapy, bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy. The management of patients with RT remains a challenge. Ongoing trials show enormous promise for newer classes of therapy in RT, with the hope being that these agents can synergize, and perhaps supersede, the current standard of care in the near future.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma. 新诊断多发性骨髓瘤的反应适应疗法。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-07-04 DOI: 10.1007/s11899-023-00704-9

Winnie Z Y Teo, Ian Y E Ong, Jason W Y Tong, Wan Li Ong, Adeline Lin, Fangfang Song, Bee Choo Tai, Melissa Ooi, Cinnie Yentia Seokojo, Yunxin Chen, Chandramouli Nagarajan, Wee Joo Chng, Sanjay de Mel

{"title":"Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.","authors":"Winnie Z Y Teo, Ian Y E Ong, Jason W Y Tong, Wan Li Ong, Adeline Lin, Fangfang Song, Bee Choo Tai, Melissa Ooi, Cinnie Yentia Seokojo, Yunxin Chen, Chandramouli Nagarajan, Wee Joo Chng, Sanjay de Mel","doi":"10.1007/s11899-023-00704-9","DOIUrl":"10.1007/s11899-023-00704-9","url":null,"abstract":"Purpose of review: The development of potent novel agents has improved outcomes for patients with multiple myeloma (MM). Heterogeneity of response to therapy, an expanding arsenal of treatment options, and cost are however major challenges for physicians making treatment decisions. Response-adapted therapy is hence an attractive strategy for sequencing of therapy in MM. Despite its successful application in other haematologic malignancies, response-adapted therapy is yet to become a standard of care for MM. We provide our perspective on response-adapted therapeutic strategies evaluated thus far and how they may be implemented and improved on in treatment algorithms of the future.Recent findings: While older studies suggested that early response based on International Myeloma Working Group response criteria could impact long-term outcomes, recent data have contradicted these findings. The advent of minimal residual disease (MRD) as a powerful prognostic factor in MM has raised the promise of MRD-adapted treatment strategies. The development of more sensitive techniques for paraprotein quantification as well as imaging modalities to detect extramedullary disease is likely to change response assessment in MM. These techniques combined with MRD assessment may provide sensitive and holistic response assessments which could be evaluated in clinical trials. Response-adapted treatment algorithms have the potential to allow an individualised treatment strategy, maximising efficacy, while minimising toxicities and cost. Standardisation of MRD methodology, incorporation of imaging into response assessment, and the optimal management of MRD positive patients are key questions to be addressed in future trials.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions. 血液系统恶性肿瘤患者的经济毒性：综述和干预的必要性。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-07-25 DOI: 10.1007/s11899-023-00707-6

Megan Sears-Smith, Thomas G Knight

{"title":"Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions.","authors":"Megan Sears-Smith, Thomas G Knight","doi":"10.1007/s11899-023-00707-6","DOIUrl":"10.1007/s11899-023-00707-6","url":null,"abstract":"Introduction: Financial toxicity is a developing research area to quantify the financial stress experienced by patients and caregivers, as well as the mechanisms by which they manage the costs associated with treatment and the very real harms that this stress can inflict upon cancer care. Patients with blood malignancies experience increased costs associated with their diagnosis due to possible inpatient admissions for treatment, frequent office visits, and even more frequent lab evaluations and testing.Purpose of review: Multiple studies have examined the causes and effects of financial toxicity on patient care and outcomes, and there have been several validated tools developed to identify patients experiencing or at risk for financial harm.Discussion: However, few studies to date have focused on implementing successful interventions to assist in mitigating financial difficulties for patients diagnosed with hematologic malignancies and their families. In this review, we examine the current literature with an emphasis on levels of care, including providers, systems, and policies. Specifically, we discuss published interventions including physician education about treatment costs, financial navigation in cancer centers, and novel institutional multidisciplinary review of patients' financial concerns. We also discuss the urgent need for societal and governmental interventions to lessen financial distress experienced by these highly vulnerable blood cancer patients.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10233397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0